Published in Clin Microbiol Rev on April 01, 2009
The occurrence and prevention of foodborne disease in vulnerable people. Foodborne Pathog Dis (2011) 1.06
Serious musculoskeletal infections in children receiving anti-tumor necrosis factor-alpha therapy: a case series. Clin Rheumatol (2010) 1.00
B cell depletion curtails CD4+ T cell memory and reduces protection against disseminating virus infection. J Immunol (2014) 0.93
Clinical characteristics of Nocardia infection in patients with rheumatic diseases. Clin Dev Immunol (2013) 0.91
[Anti-TNF-α treatment for uveitis. Analysis of the current situation]. Ophthalmologe (2011) 0.90
Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+) )-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates. Clin Exp Immunol (2011) 0.80
Lymphopenia, Infectious Complications, and Outcome in Spontaneous Intracerebral Hemorrhage. Neurocrit Care (2016) 0.79
Bloodstream infections in patients with solid tumors. Virulence (2016) 0.78
[Infectious complications of biologic therapy in patients with rheumatoid arthritis]. Z Rheumatol (2010) 0.78
Review article: BK virus in systemic lupus erythematosus. Pediatr Rheumatol Online J (2015) 0.76
Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia. Onco Targets Ther (2017) 0.75
Antigen presentation by B cells guides programing of memory CD4(+) T-cell responses to a TLR4-agonist containing vaccine in mice. Eur J Immunol (2016) 0.75
Restoring immune tolerance in neuromyelitis optica: Part I. Neurol Neuroimmunol Neuroinflamm (2016) 0.75
[Rare viral infections during immunosuppressive therapy: a "normal" side effect?]. Z Rheumatol (2011) 0.75
Cellular and Molecular Defects Underlying Invasive Fungal Infections-Revelations from Endemic Mycoses. Front Immunol (2017) 0.75
Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study. Front Pharmacol (2017) 0.75
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics (1998) 49.00
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity (1995) 10.65
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (2008) 9.94
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med (2005) 7.54
Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis (2004) 6.45
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther (2007) 5.02
Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med (2006) 4.79
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis (2003) 4.53
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol (2006) 3.38
Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum (2008) 3.36
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis (2007) 3.31
TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) (2005) 2.69
Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) (2006) 2.43
Targeted therapies: a new generation of cancer treatments. Am Fam Physician (2008) 2.36
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum (2004) 2.35
A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med (1991) 2.35
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis (2008) 2.33
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum (2007) 2.31
Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis (2006) 2.29
Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina (2008) 2.22
Tolerability and safety of rituximab (MabThera). Cancer Treat Rev (2005) 2.15
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer (2005) 2.08
ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli. Nat Med (2006) 2.03
Reduction of the total IgE level by omalizumab in children and adolescents. J Asthma (2008) 1.97
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol (2004) 1.91
TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol (2007) 1.85
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis (2007) 1.83
Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis (2006) 1.78
Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med (2005) 1.67
Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther (2007) 1.66
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum (2003) 1.64
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2000) 1.63
The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum (2004) 1.61
Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol (2008) 1.60
Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis (2008) 1.56
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis (2006) 1.56
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis (2004) 1.53
A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm (2007) 1.53
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol (2003) 1.52
Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol (2007) 1.52
Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis (2007) 1.49
A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum (2008) 1.46
Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun (2008) 1.40
Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis (2006) 1.39
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist (2007) 1.38
Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis (2005) 1.37
Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol (2006) 1.30
Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev (2007) 1.29
Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis (2005) 1.28
Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum (2006) 1.26
Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum (2004) 1.25
Drugs and their molecular targets: an updated overview. Fundam Clin Pharmacol (2008) 1.25
Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med (2006) 1.23
Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis (2006) 1.23
Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis (2008) 1.22
Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases. Clin Infect Dis (2006) 1.22
Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis (2007) 1.21
Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol (2006) 1.20
Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology (1995) 1.17
Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther (2007) 1.17
Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Ann Hematol (2007) 1.16
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol (2003) 1.16
Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med (2004) 1.15
Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am (2006) 1.12
Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum (2005) 1.11
Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol (2006) 1.11
Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J (2004) 1.11
Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol (2006) 1.09
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood (2005) 1.08
Epidermal growth factor receptor signaling to Erk1/2 and STATs control the intensity of the epithelial inflammatory responses to rhinovirus infection. J Biol Chem (2008) 1.04
Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients. J Infect (2007) 1.03
Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum (2008) 1.03
Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol (2005) 1.02
Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin Neuropathol (2007) 1.02
Type I reaction of Hansen's disease with exposure to adalimumab: a case report. Arthritis Rheum (2008) 1.02
Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant (2007) 1.01
The effects of natalizumab on the innate and adaptive immune system in the central nervous system. J Neurol Sci (2008) 1.00
Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis (2005) 0.99
Certolizumab pegol. Nat Rev Drug Discov (2008) 0.98
The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol Assess (2004) 0.98
Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer. J Clin Oncol (2007) 0.97
Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J (2005) 0.97
Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs (2003) 0.96
An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther (2005) 0.96
Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. Clin Exp Med (2006) 0.95
Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol (2008) 0.94
ErbB-directed immunotherapy: antibodies in current practice and promising new agents. Immunol Lett (2007) 0.93
Mycobacterium avium complex olecranon bursitis in a patient treated with alefacept. Mayo Clin Proc (2005) 0.92
FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. J Nucl Med (2000) 0.91
Hormonal contraception and the risk of HIV acquisition. AIDS (2007) 5.05
Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis (2008) 3.98
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14
Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis (2011) 2.35
Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS (2010) 2.23
Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother (2010) 1.94
Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women. J Acquir Immune Defic Syndr (2008) 1.80
Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sex Transm Dis (2009) 1.73
Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS (2010) 1.68
Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe. AIDS (2007) 1.45
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS (2012) 1.38
Current concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus. J Med Microbiol (2012) 1.25
Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial. PLoS One (2013) 1.24
Career outcomes of the graduates of the American Board of Internal Medicine Research Pathway, 1995-2007. Acad Med (2013) 1.24
Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS One (2012) 1.13
Unprotected sex following HIV testing among women in Uganda and Zimbabwe: short- and long-term comparisons with pre-test behaviour. Int J Epidemiol (2009) 1.10
A cross-sectional description of social capital in an international sample of persons living with HIV/AIDS (PLWH). BMC Public Health (2012) 1.07
Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe. J Acquir Immune Defic Syndr (2011) 1.06
First trial of the HIV-1 vaccine in Africa: Ugandan experience. BMJ (2002) 1.06
Kinetics of myeloid and lymphocyte recovery and infectious complications after unrelated umbilical cord blood versus HLA-matched unrelated donor allogeneic transplantation in adults. Br J Haematol (2004) 1.03
Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients. J Infect (2007) 1.03
Increases in human papillomavirus detection during early HIV infection among women in Zimbabwe. J Infect Dis (2011) 1.01
Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity. J Clin Virol (2008) 0.99
Men's circumcision status and women's risk of HIV acquisition in Zimbabwe and Uganda. AIDS (2007) 0.98
Current and novel antibiotics against resistant Gram-positive bacteria. Infect Drug Resist (2008) 0.98
Cefotaxime-resistant bacteria colonizing older people admitted to an acute care hospital. J Am Geriatr Soc (2003) 0.97
Age, stress, and isolation in older adults living with HIV. AIDS Care (2013) 0.97
Male circumcision and women's risk of incident chlamydial, gonococcal, and trichomonal infections. Sex Transm Dis (2008) 0.97
The role of vitamin D deficiency in sepsis and potential therapeutic implications. J Infect (2011) 0.96
A qualitative description of women's HIV self-management techniques: context, strategies, and considerations. J Assoc Nurses AIDS Care (2011) 0.93
Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success. J Infect Dis (2011) 0.93
A cross-sectional description of age and gender differences in exercise patterns in adults living with HIV. J Assoc Nurses AIDS Care (2014) 0.92
An update on the association of vitamin D deficiency with common infectious diseases. Can J Physiol Pharmacol (2015) 0.92
Oropharyngeal colonization by Streptococcus pneumoniae among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility. Int J Infect Dis (2006) 0.90
Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. AIDS (2013) 0.90
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario. Vaccine (2013) 0.89
Improving sleep hygiene behavior in adults living with HIV/AIDS: a randomized control pilot study of the SystemCHANGE(TM)-HIV intervention. Appl Nurs Res (2012) 0.89
Management of rheumatic heart disease in uganda: the emerging epidemic of non-AIDS comorbidity in resource-limited settings. J Acquir Immune Defic Syndr (2014) 0.89
Use of vaporized hydrogen peroxide decontamination during an outbreak of multidrug-resistant Acinetobacter baumannii infection at a long-term acute care hospital. Infect Control Hosp Epidemiol (2010) 0.87
The impact of social context on self-management in women living with HIV. Soc Sci Med (2013) 0.87
Measuring HIV self-management in women living with HIV/AIDS: a psychometric evaluation study of the HIV Self-management Scale. J Acquir Immune Defic Syndr (2012) 0.86
Multihospital outbreak of Clostridium difficile infection, Cleveland, Ohio, USA. Emerg Infect Dis (2010) 0.85
Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay. J Acquir Immune Defic Syndr (2014) 0.84
A family cluster of five cases of group A streptococcal pneumonia. Pediatrics (2003) 0.82
Role of fecal incontinence in contamination of the environment with vancomycin-resistant enterococci. Am J Infect Control (2003) 0.81
An exploration of the psychologic impact of contact isolation on patients in Singapore. Am J Infect Control (2013) 0.80
Gentian violet exhibits activity against biofilms formed by oral Candida isolates obtained from HIV-infected patients. Antimicrob Agents Chemother (2011) 0.79
A case study of a real-time evaluation of the risk of disease transmission associated with a failure to follow recommended sterilization procedures. Antimicrob Resist Infect Control (2014) 0.79
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. J Interferon Cytokine Res (2008) 0.79
Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D. AIDS Res Hum Retroviruses (2014) 0.78
Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial. PLoS One (2013) 0.78
New entrants to HIV care are presenting only at marginally earlier stages of disease but may increasingly represent groups perceived at lower risk. J Int Assoc Physicians AIDS Care (Chic) (2005) 0.78
Thermoregulation and risk of surgical site infection. Infect Control Hosp Epidemiol (2011) 0.77
Hormonal contraceptive use and discontinuation among HIV-infected women in Uganda and Zimbabwe. J Acquir Immune Defic Syndr (2013) 0.77
Interleukin 12 and interferon-gamma synthetic deficiency is associated with dendritic cell cytopenia after cardiac surgery. Shock (2005) 0.77
The Impact of Mental Wellness on HIV Self-Management. J Assoc Nurses AIDS Care (2016) 0.76
Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants. AIDS (2017) 0.75
Determinants of clinician knowledge on aging and HIV/AIDS: a survey of practitioners and policy makers in Kampala District, Uganda. PLoS One (2013) 0.75
Brief Report: Prevalence of Latent Rheumatic Heart Disease Among HIV-Infected Children in Kampala, Uganda. J Acquir Immune Defic Syndr (2016) 0.75
Ethical issues in microbicide clinical trials for HIV prevention. Curr HIV Res (2012) 0.75